For the past several years, success has grown more elusive for American biotech firms, navigating a dramatically altered landscape that…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
For decades, metabolic dysfunction-associated steatohepatitis (MASH), a more serious inflammatory form of fatty liver disease, remained a largely overlooked condition,…
Read More
American Diabetes Association Conference: Groundbreaking GLP-1 Discoveries Eclipsed by Scientific Freedom Protest
The annual scientific sessions of the American Diabetes Association (ADA) this week served as a dual stage: a vibrant forum…
Read More
CEPI Fast-Tracks Three Ebola Vaccine Candidates from IAVI, Moderna, and Oxford Amidst Bundibugyo Outbreak in DRC and Uganda
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating…
Read More
J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potential treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast, untapped reservoir…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The United States Food and Drug Administration (FDA) embarked on a pivotal initiative in June 2025 with the announcement of…
Read More
Calderasib’s real innovation: designed for combinability and potency
Merck has unveiled its investigational KRAS G12C inhibitor, calderasib, positioning it not merely as another potent molecule in a rapidly…
Read More
FUJIFILM Biotechnologies COO Maja Herold Pedersen on AI, autonomy and the path from quality to operations
FUJIFILM Biotechnologies, a prominent contract development and manufacturing organization (CDMO), is currently executing a monumental expansion strategy, with approximately $7…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
